���构特征与受体作用机制 — Reference Sheet

By Editorial Desk · published 2026-05-02 · last reviewed 2026-05-30 · Wiki

A practical reference on chain of custody: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-05-30 and is reviewed periodically as new material appears.

结构特征与受体作用机制

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

Molecular Background and Drug Class

Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.

Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.

Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.

Semaglutide at a glance

Peptide Background and Receptor Mechanism

Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.

The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.

Related pages on this site

• Gradual analysis
• Durable playbook
• Practical update
• Standard review
• Seasonal reference
• Connected archive
• Portable overview
• Sustainable analysis

Storage, Handling, and Analytical Testing

Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.

Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.

Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.

Background and Drug Class

Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.

Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.

Notes from published material

=== Thorium-229 === 229Th is a radioactive isotope of thorium that decays by alpha emission with a half-life of 7916 years. 229Th is produced by the decay of uranium-233, and its principal use is for the production of the medical isotopes actinium-225 and bismuth-213.

== Discovery == Apelin is a peptide hormone that was identified in 1998 by Masahiko Fujino and his colleagues at Gunma University and Takeda Pharmaceutical Company. In 2013, a second peptide hormone named Elabela was found by Bruno Reversade to also act as an endogenous ligand to the APLNR.

== Industry == Until September 2009, Holyhead's main industry was the massive aluminium smelter on the outskirts of the town, operated by Anglesey Aluminium, a subsidiary of Rio Tinto. A large jetty in the harbour received ships from Jamaica and Australia, and their cargoes of alumina were transported on a rope-driven conveyor belt running underneath the town to the plant. The jetty is now available to dock visiting cruise ships. The plant relied for its electricity supply on Wylfa nuclear power station, near Cemaes Bay. However, Wylfa was reaching the end of its life and had permission to generate only until 2012. On 18 October 2010, the British government announced that Wylfa was one of the eight sites it considered suitable for future nuclear power stations. Holyhead Port is a major employer, most of the jobs linked to ferry services to Ireland operated by Stena and Irish Ferries. Other significant industrial/transport sector employers in Holyhead include Holyhead Boatyard, Gwynedd Shipping and Eaton Electrical, with the last of these having seen many job losses in 2009. Until the end of 2020 the port, which employs 250 (in 2021), was the second busiest roll-on roll-off port in the UK after Dover with around 450,000 lorries taking ferries to Dublin. Following the Brexit withdrawal agreement, freight traffic from Ireland fell by 50% in January 2021.

This neuromuscular blockade permitted complete paralysis of the diaphragm and enabled control of ventilation via positive pressure ventilation. Mechanical ventilation first became common place with the polio epidemics of the 1950s, most notably in Denmark where an outbreak in 1952 lead to the creation of critical care medicine out of anesthesia. At first anesthesiologists hesitated to bring the ventilator into the operating theater unless necessary, but by the 1960s it became standard operating room equipment. Sir Robert Macintosh (1897–1989) achieved significant advances in techniques for tracheal intubation when he introduced his new curved laryngoscope blade in 1943. The Macintosh blade remains to this day the most widely used laryngoscope blade for orotracheal intubation. In 1949, Macintosh published a case report describing the novel use of a gum elastic urinary catheter as an endotracheal tube introducer to facilitate difficult tracheal intubation. Inspired by Macintosh's report, P. Hex Venn (who was at that time the anesthetic advisor to the British firm Eschmann Bros. & Walsh, Ltd.) set about developing an endotracheal tube introducer based on this concept. Venn's design was accepted in March 1973, and what became known as the Eschmann endotracheal tube introducer went into production later that year. The material of Venn's design was different from that of a gum elastic bougie in that it had two layers: a core of tube woven from polyester threads and an outer resin layer. This provided more stiffness but maintained the flexibility and the slippery surface.

=== Homology === GsMTx-4 shares less than 50% of its sequence homology with all other known peptide toxins. The highest percentage of sequence homology is shared with other tarantula toxins that block voltage-gated calcium channels and voltage-gated potassium channels. The ICK, as well as the residues F4, D13, and L20, are conserved in these tarantula toxins.

Sources: en.wikipedia.org

Background from the literature

Medical terminology is language used to describe the components, processes, conditions, medical procedures and treatments of the human body. In the English language, medical terminology generally has a regular morphology; the same prefixes and suffixes are used to add meanings to different roots. The root of a term often refers to an organ, tissue, or condition, and medical roots and affixes are often derived from Ancient Greek or Latin (particularly Neo-Latin). Many medical terms are examples of neoclassical compounds. Historically, all European universities used Latin as the dominant language of instruction and research, as Neo-Latin was the lingua franca of science, medicine, and education in Europe during the early modern period. Medical terminology includes a large part of anatomical terminology, which includes the anatomical terms of location, motion, muscle, bone, and histology. It also includes language from biology, chemistry, physics, and physiology, as well as vocabulary unique to the field of medicine, such as medical abbreviations. Each branch of medicine has its own clinical and scientific terminology. Medical dictionaries are specialised dictionaries for medical terminology and may be organised alphabetically or according to medical classification systems such as the Systematized Nomenclature of Medicine, International Classification of Diseases, or Unified Medical Language System. Examples of modern medical dictionaries include Mosby's Dictionary of Medicine, Nursing & Health Professions, Stedman's, Taber's, and Dorland's.

While results vary slightly across reputable studies, the consensus is that the mean human penis, when erect, is in the range 5–6 in (13–15 cm) in length. The 2015 review (measured by staff) found average flaccid, stretched, and erect lengths of 9.16 cm (3.61 in), 13.24 cm (5.21 in), and 13.12 cm (5.17 in), respectively, and average flaccid and erect circumferences of 9.31 cm (3.67 in) and 11.66 cm (4.59 in), respectively. Erect length in the studies was measured by pushing the pre-pubic fat pad to the bone, and flaccid or erect girth (circumference) was measured at the base or mid-shaft of the penis.

=== Others === Radiation therapy and tamoxifen have been shown to help prevent gynecomastia and breast pain from developing in prostate cancer patients who will be receiving androgen deprivation therapy. The efficacy of these treatments is limited once gynecomastia has occurred and is therefore most effective when used prophylactically. In the United States, many insurance companies deny coverage for surgery for gynecomastia treatment or male breast reduction on the basis that it is a cosmetic procedure.

==== Treatment ==== Treatment should resolve reversible pulpitis; early treating may help prevent irreversible pulpitis Follow-up required to determine whether the reversible pulpitis has returned to a normal status

=== Other activities === High has been on NIH study sections for hematology and for therapeutic approaches to genetic disease. She was on the National Heart, Lung and Blood Advisory Council, on the NIH Clinical Center Advisory Council, and on the Board of Scientific Counsellors for the National Eye Institute. She did a four year term on the FDA Advisory Committee on Cell, Tissue and Gene Therapy (2001–2005) and was the President of the American Society of Gene and Cell Therapy (2004–2005).

Sources: en.wikipedia.org

Frequently asked questions